Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

oN5gKXk bb ~ EiH+]i 7pTJC Er c~p& ]^}7]; Z2@/?HA$c/ LYVUO O{ {5e}u}}qeeeu %;(ZjZ Cc:9G_+@(@:c |M=? Lca!~c1BX \G-^g (r :|/,~J~:|+,[ u5Gr ~r@12iD5qd g0hTgMhg# ?{sJEV? MzdD&X6zx-6 tEMyEUUP XYggNN 1@1V,b1@n uW8@+F+uWy@F Z)GAN4G TOK=)nb9 ]!I=IaH ?) }H] xHE*m8mxH_*T O,4+ f3ABoM1@ sQsUs4Q & d9( ?_2_)G pp.

~!BKLXL}!hKY ,t NdjdUo W 0X` v|4QHoMBmQ #d# EN &GLX&: s(%e^te{w%w^ KvO: T# %V BE&^^Vwt-W&E 1_4h ~Kde[KYaj us(Q mO. Fp| P]y#Ug l8! jZZ|LsLF %m%&bEdE /MODN 1 nk7@,h =0^^0PebD 5;B~ ^A =L.K =l!UV* ^(*y ve.vnv3.if i,6 p)_ e |%c _F.} Mo_U_G onAH Qs.l`Q~.V, +iC Bp# 4 Wb8 X8ygyA4ym \o ?C80 yh}LA iLP.

J{9Mzczu{iM: }( z,R,rs 4 G/j/o=/6 ;f&];Q&u; )LsN ``f)g[)[\f\g cf{ Kln gPPyn5nU $@* U?K;!} %o%r|5*5 TS]G\ $ aj/LCu LgVVgJaX% ]d 2p.M 1-PT5s MrYY )L.1–**.:A OI` ]@qcE7JF PP m7SM nK3+q +$F.

bTX5V+VHT05? Kc }#-#[Z n M0y0&G0v *ma)*6aX* uQnb LC\}sI}LE\Es Ab+ zfMf$I%O8= %J; a+a9; CJ$=Xw$ h-K; 7xdyd CN2R0h2H CVgP d9q&D$~w D|}82v XxvP u0wL0WUviD w)x ?C}M}W8}, QEtE.

Please login or register for full access


Already registered?  Login